Bicara Therapeutics (BCAX) Total Current Liabilities (2023 - 2026)

Bicara Therapeutics' Total Current Liabilities history runs 4 years deep, the most recent figure standing at $39.3 million for Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 105.75% year-over-year to $39.3 million in Q1 2026; TTM through Mar 2026 was $39.3 million, a 105.75% increase from a year earlier, with the FY2025 full-year figure at $28.9 million, up 60.92% from the prior year.
• Total Current Liabilities advanced to $39.3 million in Q1 2026 per BCAX's latest filing, from $28.9 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $39.3 million in Q1 2026 and bottomed at $14.5 million in Q3 2024.
• The 4-year median for Total Current Liabilities is $18.6 million (2024), against an average of $21.7 million.
• Across the five-year window, Total Current Liabilities rose 19.26% in 2024 and jumped 105.75% in 2026, its largest moves.
• Year by year, Total Current Liabilities stood at $15.1 million in 2023, then climbed by 19.26% to $18.0 million in 2024, then soared by 60.92% to $28.9 million in 2025, then surged by 35.89% to $39.3 million in 2026.
• Per Business Quant, the three latest BCAX Total Current Liabilities figures stand at $39.3 million (Q1 2026), $28.9 million (Q4 2025), and $21.0 million (Q3 2025).